Budesonide-Dependent Modulation of Expression of Macrophage Migration Inhibitory Factor in a Polyposis Model: Evidence for Differential Regulation in Surface and Glandular Epithelia
Restricted accessResearch articleFirst published online July, 2004
Budesonide-Dependent Modulation of Expression of Macrophage Migration Inhibitory Factor in a Polyposis Model: Evidence for Differential Regulation in Surface and Glandular Epithelia
Macrophage migration inhibitory factor (MIF) is a counterregulatory lymphokine for glucocorticoid action within the immune system. To provide further insights into the way expression of pleiotropically acting MIF is modulated by glucocorticoids, we investigated the influence of the glucocorticoid budesonide on the level of expression of MIF in a model of human nasal polyposis by quantitative immunohistochemical analysis. Ten nasal polyps obtained from surgical resection were maintained for 24 hours in the presence of 3 budesonide concentrations: 10, 50, and 250 ng/mL. As quantitatively demonstrated by computer-assisted microscopy, 50 ng/mL induced an increase in MIF expression in the surface epithelium and a decrease in MIF expression in the glandular epithelium. At the 250 ng/mL dose, the inverse effect was induced. Evidently, surface and glandular epithelia react nonuniformly to the glucocorticoid regarding MIF presence, adding dependence on the cell type to the regulatory network.
StoopAEvan der HeijdenHABiewengaJvan der BaanS. Eosinophils in nasal polyps and nasal mucosa: An immunohistochemical study. J Allergy Clin Immunol1993; 91: 616–22.
2.
BernsteinJMGorfienJNobleB. Role of allergy in nasal polyposis: A review. Otolaryngol Head Neck Surg1995; 113: 724–32.
3.
MygindN. Advances in the medical treatment of nasal polyps. Allergy1999; 54(suppl 53): 12–6.
4.
BloomBRBennettB. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science1966; 153: 80–2.
5.
DavidJR. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell–antigen interaction. Proc Natl Acad Sci USA1966; 56: 72–7.
6.
ParantMLe ContelCParantFChedidL. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res1991; 10: 265–71.
7.
WeiserWYTemplePAWitek-GiannottiJSRemoldHGClarkSCDavidJR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA1989; 86: 7522–6.
8.
CalandraTBucalaR. Macrophage migration inhibitory factor (MIF): A glucocorticoid counter-regulator within the immune system. Crit Rev Immunol1997; 17: 77–88.
9.
NishihiraJ. Macrophage migration inhibitory factor (MIF): Its essential role in the immune system and cell growth. J Interferon Cytokine Res2000; 20: 751–62.
10.
HonmaNKosekiHAkasakaT. Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia. Immunology2000; 100: 84–90.
11.
ApteRSSinhaDMayhewEWistowGJNiederkornJY. Cutting edge: Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol1998; 160: 5693–6.
12.
ShimizuTOhkawaraANishihiraJSakamotoW. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization. FEBS Lett1996; 381: 199–202.
13.
DonnellySCHaslettCReidPT. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med1997; 3: 320–3.
14.
LeechMMetzCHallP. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum1999; 42: 1601–8.
15.
KitaichiNKotakeSSasamotoY. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci1999; 40: 247–50.
16.
MurakamiHAkbarSMMatsuiHOnjiM. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: Clinical implications and pathogenic significance. Eur J Clin Invest2001; 31: 337–43.
17.
de JongYPAbadia-MolinaACSatoskarAR. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol2001; 2: 1061–6.
18.
HuangXRChun HuiCWChenYX. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology2001; 121: 619–30.
19.
OhwatariRFukudaSIwabuchiKInuyamaYOnoeKNishihiraJ. Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener's granulomatosis and relapsing polychondritis. Ann Otol Rhinol Laryngol2001; 110: 1035–40.
20.
OnoderaSTanjiHSuzukiK. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine1999; 11: 163–7.
21.
KorsgrenMKallstromLUllerL. Role of macrophage migration inhibitory factor (MIF) in allergic and endotoxin-induced airway inflammation in mice. Mediators Inflamm2000; 9: 15–23.
22.
ShimizuTAbeROhkawaraANishihiraJ. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immunol1999; 104: 659–64.
23.
CalandraTBernhagenJMetzCN. MIF as a glucocorticoid-induced modulator of cytokine production. Nature1995; 377: 68–71.
24.
DonnellySCBucalaR. Macrophage migration inhibitory factor: A regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today1997; 3: 502–7.
25.
ZengFYWeiserWYKratzinHStahlBKarasMGabiusHJ. The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys1993; 303: 74–80.
26.
KayserKBovinNVKorchaginaEYZeilingerCZengFYGabiusHJ. Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur J Cancer1994; 30A: 653–7.
27.
NagyNDecaesteckerCDongX. Characterization of ligands for galectins, natural galactoside-binding immunoglobulin G subfractions and sarcolectin and also of the expression of calcyclin in thyroid lesions. Histol Histopathol2000; 15: 503–13.
28.
CambyINagyNLopesMB. Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. Brain Pathol1999; 9: 1–19.
29.
HassidSDecaesteckerCHermansC. Algorithm analysis of lectin glycohistochemistry and Feulgen cytometry for a new classification of nasal polyposis. Ann Otol Rhinol Laryngol1997; 106: 1043–51.
30.
CambyISalmonIDanguyA. Influence of gastrin on human astrocytic tumor cell proliferation. J Natl Cancer Inst1996; 88: 594–600.
31.
JanssenTPeteinMvan VelthovenR. Coregulatory effects of epidermal growth factor, dihydrotestosterone and prolactin on benign human prostatic hyperplasia tissue culture proliferation. Prostate1997; 30: 47–52.
32.
PhilippartPHarperLChaboteauxC. Homocamptothecin, an E-ring–modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res2000; 6: 1557–62.
33.
GabiusHJDarroFRemmelinkM. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest2001; 19: 114–26.
34.
RosengrenEBucalaRAmanP. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med1996; 2: 143–9.
LeechMMetzCBucalaRMorandEF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum2000; 43: 827–33.
38.
DelbrouckCDoyenIBelotN. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest2002; 82: 147–58.
39.
DelbrouckCKaltnerHDanguyA. Glucocorticoid-induced differential expression of the sialylated and nonsialylated Lewisa epitopes and respective binding sites in human nasal polyps maintained under ex vivo tissue culture conditions. Ann Otol Rhinol Laryngol2002; 111: 1097–107.
40.
GabiusHJ. Probing the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1. Biochimie2001; 83: 659–66.
